Experience from Turkish centers participating in the Early Access Program (EAP): Preliminary real-world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treated advanced melanoma patients

Objective: We aimed to evaluate the safety of nivolumab + ipilimumab (nivo + ipi) in advanced melanoma patients who had relapsed after ≥1 line of systemic treatment in a real-world setting. Methods: Adult patients with advanced melanoma who had progressed after ≥1 line of systemic treatment were eli...

Cijeli opis

Bibliografski detalji

Glavni autori:	Nuri Karadurmus, Mehmet Ali Nahit Sendur, Burcak Karaca, Omer Fatih Olmez, Ilhan Hacibekiroglu, Hasan Senol Coskun, Serkan Degirmencioglu, Yasemin Kemal, Saadettin Kilickap, Ahmet Taner Sumbul, Burc Aydin, Hande Turna, Muhammet Ali Kaplan, Nalan Babacan, Umut Demirci, Alper Ata, Dilek Erdem, Ahmet Ozet, Huseyin Abali
Format:	Artigo
Jezik:	Inglês
Izdano:	Turkish Society of Oncology 2018-12-01
Serija:	Journal of Oncological Sciences
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2452336418300542
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!